Switch to:
Also traded in: Germany, Japan

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
ALPMY's Cash-to-Debt is ranked higher than
94% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.09 vs. ALPMY: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ALPMY' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.07  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.71
ALPMY's Equity-to-Asset is ranked higher than
63% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. ALPMY: 0.71 )
Ranked among companies with meaningful Equity-to-Asset only.
ALPMY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.7  Med: 0.75 Max: 0.78
Current: 0.71
0.7
0.78
Interest Coverage 110.60
ALPMY's Interest Coverage is ranked higher than
50% of the 635 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 105.95 vs. ALPMY: 110.60 )
Ranked among companies with meaningful Interest Coverage only.
ALPMY' s Interest Coverage Range Over the Past 10 Years
Min: 60.32  Med: 812.35 Max: No Debt
Current: 110.6
Piotroski F-Score: 8
Altman Z-Score: 5.51
Beneish M-Score: -2.75
WACC vs ROIC
3.11%
22.07%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 20.16
ALPMY's Operating Margin % is ranked higher than
80% of the 744 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.42 vs. ALPMY: 20.16 )
Ranked among companies with meaningful Operating Margin % only.
ALPMY' s Operating Margin % Range Over the Past 10 Years
Min: 10.25  Med: 16.52 Max: 28.37
Current: 20.16
10.25
28.37
Net Margin % 15.84
ALPMY's Net Margin % is ranked higher than
80% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.16 vs. ALPMY: 15.84 )
Ranked among companies with meaningful Net Margin % only.
ALPMY' s Net Margin % Range Over the Past 10 Years
Min: 7.09  Med: 11.72 Max: 18.24
Current: 15.84
7.09
18.24
ROE % 16.47
ALPMY's ROE % is ranked higher than
77% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. ALPMY: 16.47 )
Ranked among companies with meaningful ROE % only.
ALPMY' s ROE % Range Over the Past 10 Years
Min: 6.52  Med: 10.93 Max: 16.47
Current: 16.47
6.52
16.47
ROA % 11.75
ALPMY's ROA % is ranked higher than
83% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. ALPMY: 11.75 )
Ranked among companies with meaningful ROA % only.
ALPMY' s ROA % Range Over the Past 10 Years
Min: 5.01  Med: 8.24 Max: 12.27
Current: 11.75
5.01
12.27
ROC (Joel Greenblatt) % 88.66
ALPMY's ROC (Joel Greenblatt) % is ranked higher than
93% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.40 vs. ALPMY: 88.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALPMY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 26.38  Med: 57.05 Max: 88.66
Current: 88.66
26.38
88.66
3-Year Revenue Growth Rate 23.00
ALPMY's 3-Year Revenue Growth Rate is ranked higher than
87% of the 607 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.70 vs. ALPMY: 23.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALPMY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 7.8 Max: 23
Current: 23
0
23
3-Year EBITDA Growth Rate 34.90
ALPMY's 3-Year EBITDA Growth Rate is ranked higher than
83% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.40 vs. ALPMY: 34.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ALPMY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 4.65 Max: 34.9
Current: 34.9
0
34.9
3-Year EPS without NRI Growth Rate 40.70
ALPMY's 3-Year EPS without NRI Growth Rate is ranked higher than
86% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. ALPMY: 40.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ALPMY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 7.65 Max: 55.4
Current: 40.7
0
55.4
GuruFocus has detected 1 Warning Sign with Astellas Pharma Inc $ALPMY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALPMY's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ALPMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major  
Compare:OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHPTY, OTCPK:PTKFY, OTCPK:SNPHY, OTCPK:GWPRF, NAS:HCM, OTCPK:TGRNF, OTCPK:BOIRF, OTCPK:HAWPF, NAS:AERI, OTCPK:MAYNF, OTCPK:VEGPF, AMEX:TXMD, NAS:RTRX, OTCPK:ABSCF, NAS:RMTI » details
Traded in other countries:YPH.Germany, 4503.Japan,
Headquarter Location:Japan
Astellas Pharma Inc is a drug manufacturing company which focuses oncology. It sells its pharmaceutical products across the globe.

Astellas Pharma is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements in order to strengthen its commercialization platforms.

Ratios

vs
industry
vs
history
PE Ratio 14.42
ALPMY's PE Ratio is ranked higher than
80% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.48 vs. ALPMY: 14.42 )
Ranked among companies with meaningful PE Ratio only.
ALPMY' s PE Ratio Range Over the Past 10 Years
Min: 4.38  Med: 16.34 Max: 104.4
Current: 14.42
4.38
104.4
PE Ratio without NRI 14.42
ALPMY's PE Ratio without NRI is ranked higher than
80% of the 544 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.85 vs. ALPMY: 14.42 )
Ranked among companies with meaningful PE Ratio without NRI only.
ALPMY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 4.38  Med: 16.34 Max: 104.45
Current: 14.42
4.38
104.45
Price-to-Owner-Earnings 14.92
ALPMY's Price-to-Owner-Earnings is ranked higher than
79% of the 293 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.45 vs. ALPMY: 14.92 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ALPMY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 14.78  Med: 26.95 Max: 151.52
Current: 14.92
14.78
151.52
PB Ratio 2.23
ALPMY's PB Ratio is ranked higher than
62% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.03 vs. ALPMY: 2.23 )
Ranked among companies with meaningful PB Ratio only.
ALPMY' s PB Ratio Range Over the Past 10 Years
Min: 1.27  Med: 2.04 Max: 3.37
Current: 2.23
1.27
3.37
PS Ratio 2.30
ALPMY's PS Ratio is ranked higher than
57% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. ALPMY: 2.30 )
Ranked among companies with meaningful PS Ratio only.
ALPMY' s PS Ratio Range Over the Past 10 Years
Min: 1.35  Med: 2.31 Max: 10.2
Current: 2.3
1.35
10.2
Price-to-Free-Cash-Flow 11.79
ALPMY's Price-to-Free-Cash-Flow is ranked higher than
78% of the 226 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.83 vs. ALPMY: 11.79 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ALPMY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 11.68  Med: 25.02 Max: 81.38
Current: 11.79
11.68
81.38
Price-to-Operating-Cash-Flow 9.23
ALPMY's Price-to-Operating-Cash-Flow is ranked higher than
77% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.62 vs. ALPMY: 9.23 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ALPMY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.16  Med: 16.05 Max: 56.47
Current: 9.23
9.16
56.47
EV-to-EBIT 9.08
ALPMY's EV-to-EBIT is ranked higher than
86% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.99 vs. ALPMY: 9.08 )
Ranked among companies with meaningful EV-to-EBIT only.
ALPMY' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.1  Med: 11.3 Max: 38.6
Current: 9.08
4.1
38.6
EV-to-EBITDA 7.41
ALPMY's EV-to-EBITDA is ranked higher than
86% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.26 vs. ALPMY: 7.41 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALPMY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.5  Med: 9.3 Max: 38.6
Current: 7.41
3.5
38.6
PEG Ratio 0.94
ALPMY's PEG Ratio is ranked lower than
82% of the 293 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.90 vs. ALPMY: 0.94 )
Ranked among companies with meaningful PEG Ratio only.
ALPMY' s PEG Ratio Range Over the Past 10 Years
Min: 0.46  Med: 1.01 Max: 9.3
Current: 0.94
0.46
9.3
Current Ratio 2.25
ALPMY's Current Ratio is ranked lower than
55% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.55 vs. ALPMY: 2.25 )
Ranked among companies with meaningful Current Ratio only.
ALPMY' s Current Ratio Range Over the Past 10 Years
Min: 2.12  Med: 2.57 Max: 3.64
Current: 2.25
2.12
3.64
Quick Ratio 1.85
ALPMY's Quick Ratio is ranked higher than
50% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.85 vs. ALPMY: 1.85 )
Ranked among companies with meaningful Quick Ratio only.
ALPMY' s Quick Ratio Range Over the Past 10 Years
Min: 1.72  Med: 2.17 Max: 3.22
Current: 1.85
1.72
3.22
Days Inventory 181.62
ALPMY's Days Inventory is ranked lower than
77% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.29 vs. ALPMY: 181.62 )
Ranked among companies with meaningful Days Inventory only.
ALPMY' s Days Inventory Range Over the Past 10 Years
Min: 118.75  Med: 138.57 Max: 181.62
Current: 181.62
118.75
181.62

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.18
ALPMY's Dividend Yield % is ranked higher than
65% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. ALPMY: 1.18 )
Ranked among companies with meaningful Dividend Yield % only.
ALPMY' s Dividend Yield % Range Over the Past 10 Years
Min: 0.85  Med: 2.46 Max: 4.39
Current: 1.18
0.85
4.39
Dividend Payout Ratio 0.33
ALPMY's Dividend Payout Ratio is ranked higher than
55% of the 410 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. ALPMY: 0.33 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ALPMY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.19  Med: 0.42 Max: 0.85
Current: 0.33
0.19
0.85
3-Year Dividend Growth Rate 7.20
ALPMY's 3-Year Dividend Growth Rate is ranked lower than
53% of the 285 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. ALPMY: 7.20 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ALPMY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 1.3  Med: 6.75 Max: 52.5
Current: 7.2
1.3
52.5
Forward Dividend Yield % 2.38
ALPMY's Forward Dividend Yield % is ranked higher than
64% of the 658 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.59 vs. ALPMY: 2.38 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.54
ALPMY's 5-Year Yield-on-Cost % is ranked higher than
63% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.09 vs. ALPMY: 1.54 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ALPMY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.1  Med: 3.18 Max: 5.68
Current: 1.54
1.1
5.68
3-Year Average Share Buyback Ratio 2.00
ALPMY's 3-Year Average Share Buyback Ratio is ranked higher than
96% of the 442 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. ALPMY: 2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALPMY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -12.8  Med: 2.4 Max: 0
Current: 2
-12.8
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 8.02
ALPMY's Price-to-Net-Current-Asset-Value is ranked lower than
55% of the 443 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.16 vs. ALPMY: 8.02 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ALPMY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.2  Med: 4.81 Max: 9.8
Current: 8.02
2.2
9.8
Price-to-Tangible-Book 3.86
ALPMY's Price-to-Tangible-Book is ranked lower than
54% of the 705 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.61 vs. ALPMY: 3.86 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ALPMY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.46  Med: 2.62 Max: 4.87
Current: 3.86
1.46
4.87
Price-to-Intrinsic-Value-Projected-FCF 1.27
ALPMY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
72% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. ALPMY: 1.27 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ALPMY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.26  Med: 1.86 Max: 2.4
Current: 1.27
1.26
2.4
Price-to-Median-PS-Value 0.98
ALPMY's Price-to-Median-PS-Value is ranked higher than
56% of the 645 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. ALPMY: 0.98 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALPMY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.59  Med: 0.98 Max: 4.03
Current: 0.98
0.59
4.03
Price-to-Peter-Lynch-Fair-Value 0.57
ALPMY's Price-to-Peter-Lynch-Fair-Value is ranked higher than
88% of the 174 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. ALPMY: 0.57 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ALPMY' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.42  Med: 1.52 Max: 5.89
Current: 0.57
0.42
5.89
Price-to-Graham-Number 1.57
ALPMY's Price-to-Graham-Number is ranked higher than
65% of the 408 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.35 vs. ALPMY: 1.57 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ALPMY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.72  Med: 1.51 Max: 2.63
Current: 1.57
0.72
2.63
Earnings Yield (Greenblatt) % 11.00
ALPMY's Earnings Yield (Greenblatt) % is ranked higher than
90% of the 1046 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.36 vs. ALPMY: 11.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALPMY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.6  Med: 8.8 Max: 24.4
Current: 11
2.6
24.4
Forward Rate of Return (Yacktman) % 34.77
ALPMY's Forward Rate of Return (Yacktman) % is ranked higher than
83% of the 369 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.72 vs. ALPMY: 34.77 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ALPMY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -10.2  Med: 7.7 Max: 34.77
Current: 34.77
-10.2
34.77

More Statistics

Revenue (TTM) (Mil) $12,060
EPS (TTM) $ 0.90
Beta0.43
Short Percentage of Float0.00%
52-Week Range $12.16 - 19.40
Shares Outstanding (Mil)2,056.98
» More Articles for ALPMY

Headlines

Articles On GuruFocus.com
Astellas Names Shontelle Dodson Senior Vice President and Head of Medical Affairs Americas May 11 2017 
Astellas Announces Decision to Discontinue ASP8273 Treatment and Close Randomization for Clinical St May 10 2017 
Astellas Announces Key Leadership Promotions in Development Organization Apr 28 2017 
Astellas to Acquire Ogeda SA Apr 02 2017 
Charles de Vaulx's IVA Funds Semi-Annual Update Call Transcript Sep 27 2016 
Charles De Vaulx Comments on Astellas Pharma Inc. Jun 06 2016 
Charles de Vaulx's Annual IVA Funds Letter from the Portfolio Managers Jun 06 2016 
IVA Worldwide Fund Quarterly Review - Fourth Quarter 2015 Jan 22 2016 
Astellas Pharma: Outstanding Growth, Undervalued Dec 14 2015 
Astellas Pharma Has Been Growing for Years and Is Underpriced Dec 11 2015 

More From Other Websites
Astellas Announces Oncology Portfolio Updates May 17 2017
Astellas Completes Acquisition of Ogeda SA May 16 2017
Astellas Names Shontelle Dodson Senior Vice President and Head of Medical Affairs Americas May 11 2017
Astellas Announces Decision to Discontinue ASP8273 Treatment and Close Randomization for Clinical... May 10 2017
Astellas Announces Key Leadership Promotions in Development Organization Apr 28 2017
Astellas Pharma, Inc. : ALPMY-US: Dividend Analysis : March 31st, 2017 (record date) : By the... Apr 20 2017
ETFs with exposure to Astellas Pharma, Inc. : April 5, 2017 Apr 05 2017
Money is pouring in to a hot new area of science that could change the way we think about aging Apr 05 2017
Astellas to Acquire Ogeda SA Apr 02 2017
ETFs with exposure to Astellas Pharma, Inc. : February 14, 2017 Feb 14 2017
Astellas Pharma, Inc. :ALPMY-US: Earnings Analysis: Q3, 2017 By the Numbers : February 8, 2017 Feb 08 2017
Astellas Pharma, Inc. : ALPMY-US: Dividend Analysis : September 29th, 2016 (record date) : By the... Jan 30 2017
Ironwood/Astellas Report Positive Phase III Data on Linzess Jan 30 2017
ETFs with exposure to Astellas Pharma, Inc. : January 20, 2017 Jan 20 2017
Astellas to Present at J.P. Morgan Healthcare Conference Dec 21 2016
Astellas Completes Acquisition of Ganymed Pharmaceuticals Dec 21 2016
ETFs with exposure to Astellas Pharma, Inc. : December 19, 2016 Dec 19 2016
Should Biopharma Companies Buy Innovation? Nov 14 2016
GUINNESS WORLD RECORDS™ Title Achieved for Organ Donor Registrations Nov 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)